Peptide News Digest

#Insulin

2 stories

Research · View digest

IIT Bombay's Injectable Peptide Amyloid Gel Released Insulin for 90 Hours and Kept Diabetic Rats' Blood Sugar Normal for 60

Researchers at IIT Bombay and Mumbai's Institute of Chemical Technology built an injectable hydrogel from functional amyloid peptides that kept insulin stable and released it over 90 hours in lab tests. One injection under the skin brought diabetic rats' glucose to normal within 30 minutes and held it for 60 hours before it rose again at 66 hours, far longer than free insulin. Adding sodium alginate let the team tune the release rate.

Regulatory · View digest

FDA Approves Lilly's Onswik (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin for Adults With Type 2 Diabetes

Eli Lilly announced on Thursday, September 24, 2026 that the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin used with diet and exercise to control blood sugar in adults with type 2 diabetes; it is not for type 1 diabetes because of an increased risk of severe hypoglycemia. Approval rests on four Phase 3 QWINT trials in more than 3,400 adults, in which efsitora met non-inferiority for A1C reduction against daily insulin glargine (QWINT-1, n=795; QWINT-4, n=730) and insulin degludec (QWINT-2, n=928; QWINT-3, n=986). Onswik will come in U-500 and U-1,000 prefilled pens delivering up to 400 and 800 units per injection, and Lilly expects U.S. availability in the coming months. It is already approved in the European Union, Mexico, and Japan.